Trial Profile
A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 7423 (Primary)
- Indications Colorectal cancer; Endometrial cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 02 Jun 2017 Results (n=69) of this and other phase I,first in human study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 24 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 09 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.